Interruption of endometrial maturation without hormonal changes by an antiprogesterone during the first half of luteal phase of the menstrual cycle: a contraceptive potential**Supported by the San Diego Reproductive Medicine Research and Educational Foundation, San Diego, California and conducted, in part, by the Mellon Foundation, New York, New York.

This publication has 21 references indexed in Scilit:

• Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis
  Fertility and Sterility, 1991
• Antiprogestin treatment decreases midluteal luteinizing hormone pulse amplitude and primarily exerts a pituitary inhibition
  American Journal of Obstetrics and Gynecology, 1990
• Contragestion and Other Clinical Applications of RU 486, an Antiprogesterone at the Receptor
  Science, 1989
• The effects of progesterone receptor blockade in the luteal phase of normal fertile women
  Fertility and Sterility, 1988
• Pharmacodynamics of the antiprogesterone RU486 in women after oral administration
  Fertility and Sterility, 1988
• Effects of an Antiprogesterone (RU486) on the Hypothalamic-Hypophyseal-Ovarian-Endometrial Axis During the Luteal Phase of the Menstrual Cycle*
  Journal of Clinical Endocrinology & Metabolism, 1988
• Late Luteal Phase Administration of RU486 for Three Successive Cycles Does Not Disrupt Bleeding Patterns or Ovulation*
  Journal of Clinical Endocrinology & Metabolism, 1987
• Disruption of Follicular Maturation and Delay of Ovulation after Administration of the Antiprogesterone RU486*
  Journal of Clinical Endocrinology & Metabolism, 1987
• The Progesterone Antagonist RU 486
  New England Journal of Medicine, 1987
• RU 486: a steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of day.
  Proceedings of the National Academy of Sciences, 1984